La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 1/6 |
| Performances passées | 2/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
WA
Based on Analyst Price Targets
Cost Efficiency And Digital Strategy Propel Earnings Amidst Pharma Industry Challenges
US$224.01
FV
11.5% undervalued intrinsic discount4.12%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
about 11 hours agoauthor updated this narrative
Charles River Laboratories International, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$198.31 |
| Plus haut sur 52 semaines | US$275.00 |
| Plus bas sur 52 semaines | US$161.65 |
| Bêta | 1.36 |
| 1Variation sur 1 mois | 0.28% |
| Variation sur 3 mois | -1.57% |
| Variation sur 1 an | 2.54% |
| 3Variation sur 3 ans | -50.23% |
| Variation sur 5 ans | 50.37% |
| Évolution depuis l'introduction en bourse | 801.41% |
Nouvelles et mises à jour récentes
Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10
US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Recent updates
Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Jul 11Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Rendement pour les actionnaires
| CRL | US Life Sciences | US Marché | |
|---|---|---|---|
| 7D | -2.7% | 0.3% | 0.7% |
| 1Y | 2.5% | 12.6% | 32.3% |
Rendement vs Industrie: CRL a sous-performé le secteur US Life Sciences qui a rapporté 7.1 % au cours de l'année écoulée.
Rendement vs marché: CRL a sous-performé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.
Volatilité des prix
| CRL volatility | |
|---|---|
| CRL Average Weekly Movement | 6.0% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: CRL n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.
Volatilité au fil du temps: La volatilité hebdomadaire de CRL ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1947 | 21,100 | Jim Foster | www.criver.com |
Charles River Laboratories International, Inc. fournit des services de découverte de médicaments, de développement non clinique et de tests de sécurité aux États-Unis, en Europe, au Canada, dans la région Asie-Pacifique et au niveau international. Ses activités s'articulent autour de trois segments : Research Models and Services (RMS), Discovery and Safety Assessment (DSA) et Manufacturing Solutions (Manufacturing). Le segment RMS produit et vend des rongeurs, des rats et des souris spécialement élevés pour les chercheurs.
Charles River Laboratories International, Inc. Résumé des fondamentaux
| CRL statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$10.24b |
| Bénéfices(TTM) | US$431.79m |
| Recettes(TTM) | US$4.08b |
23.7x
Ratio P/E2.5x
Ratio P/SLe site CRL est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CRL compte de résultat (TTM) | |
|---|---|
| Recettes | US$4.08b |
| Coût des recettes | US$2.61b |
| Marge brute | US$1.47b |
| Autres dépenses | US$1.04b |
| Les revenus | US$431.79m |
Derniers bénéfices déclarés
Jun 29, 2024
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 8.36 |
| Marge brute | 35.98% |
| Marge bénéficiaire nette | 10.59% |
| Ratio dettes/capitaux propres | 63.2% |
Quelles ont été les performances à long terme de CRL?
Voir les performances historiques et les comparaisons